Tempest Therapeutics Inc. has announced the suspension and termination of its prospectus supplement, originally filed on February 6, 2025, related to the company's common stock issuable under the Open Market Sale Agreement with Jefferies LLC. The decision, communicated on June 11, 2025, halts any sales of securities under this agreement until a new prospectus or registration statement is filed. Despite this change, the Sales Agreement itself remains effective. Further details about the Sales Agreement can be found in the company's previous Form 8-K filing with the Securities and Exchange Commission on June 20, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.